Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...3334353637383940414243...5960»
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal, HEOR:  Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial. (Pubmed Central) -  Feb 24, 2021   
    Bone-active drugs may prevent VFs in patients with active acromegaly. Low-dose SRL plus weekly pegvisomant represents a novel dosing option for achieving cost-effective, optimal biochemical control in patients with uncontrolled acromegaly requiring combination therapy.
  • ||||||||||  Journal:  Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era. (Pubmed Central) -  Feb 24, 2021   
    However, these results also suggest that endocrinologists are embracing aspects of the 'new normal' to create a novel continuum of care better suited to the presumed post-COVID-19 environment. The goal of these changes must be both to improve care while shielding patients from more severe involvement in concomitant acute illnesses such COVID-19.
  • ||||||||||  Review, Journal:  Pituitary gangliocytoma producing TSH and TRH: A review of "gangliocytomas of the sellar region". (Pubmed Central) -  Feb 20, 2021   
    Herein, we report a case of SITSH caused by an isolated pituitary gangliocytoma, expressing both TSH and TRH, which, to our best knowledge, is the first reported case of such a condition. The multidirectional differentiation and multihormonal endocrine characteristics of these tumors indicate that they are a member of neuroendocrine neoplasms, further supporting that they are derived from neural crest cells.
  • ||||||||||  [VIRTUAL] Personalized Treatment in Acromegaly () -  Feb 19, 2021 - Abstract #AACE2021AACE_33;    
    OOCs may be an effective therapy for patients with acromegaly who previously were treated with injectable SRLs. Learning Objectives: Identify predictive markers of response to different treatments of acromegalyDescribe and compare how medical treatments can help with the management of acromegaly comorbiditiesDiscuss a practical personalized approach in the treatment of acromegaly
  • ||||||||||  [VIRTUAL] A RARE CASE OF GIANT CORONARY ARTERY ANEURYSM WITH ACROMEGALY (eAbstract site) -  Feb 17, 2021 - Abstract #ACC2021ACC_1842;    
    Of note, it is usually associated with cerebral and pelvic aneurysms .These coronary aneurysms should be considered as a potential complication of acromegaly. Other more common causes of coronary artery aneurysms include atherosclerosis, Kawasaki disease, Takayasu arteritis, collagenous diseases/connective tissue disorders Marfan's, Ehlers-Danlos, Turner syndrome, and cocaine abuse.
  • ||||||||||  Journal:  DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. (Pubmed Central) -  Feb 17, 2021   
    We conclude that cAMP, which induces somatotroph proliferation and GH secretion, may concomitantly induce DNA damage, potentially linking hormone hypersecretion to SCNA and genome instability. These results elucidating somatotroph adenoma pathophysiology identify pathways for treatment targeting.
  • ||||||||||  Journal:  Deep-Learning Approach to Automatic Identification of Facial Anomalies in Endocrine Disorders. (Pubmed Central) -  Feb 16, 2021   
    Our findings suggest that the deep-learning model learned the facial characters based merely on labeled data without learning prerequisite medical knowledge, and its performance was comparable with professional medical practitioners. The model has the potential to assist in the diagnosis and follow-up of these hypersecretion statuses.
  • ||||||||||  Retrospective data, Journal:  Tratamiento quirúrgico en acromegalia: experiencia en Córdoba. (Pubmed Central) -  Feb 9, 2021   
    Conclusión: La remisión bioquímica con la cirugía fue similar a la bibliografía. No encontramos factores predictivos de remisión pero un número mayor de casos podría modificar estos resultados.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Journal:  Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly. (Pubmed Central) -  Feb 9, 2021   
    Long-term pegvisomant therapy is accompanied by increases in VAT and SAT mass that do not differ from predicted, stable SM mass and improvements in glucose metabolism. Long-term pegvisomant therapy does not produce a GH deficiency-like pattern of body composition change.
  • ||||||||||  Clinical, Journal:  Cyclooxygenase enzyme and PGE2 expression in patients with functional and non-functional pituitary adenomas. (Pubmed Central) -  Feb 5, 2021   
    Long-term pegvisomant therapy does not produce a GH deficiency-like pattern of body composition change. Data from the current study provides expression patterns of COX-1, COX-2 and PGE2 in prevalent pituitary tumors and their association with patients' clinical features which may open up new molecular targets for early diagnosis/follow up of pituitary tumor growth.
  • ||||||||||  Biomarker, Journal:  Biomarkers of Acromegaly and Growth Hormone Action. (Pubmed Central) -  Feb 5, 2021   
    Therefore, new biological markers for acromegaly and GH replacement therapy are strongly needed. The aim of this paper is to review and summarize the current state in the field pointing out new potential biomarkers for acromegaly and GH use/abuse.
  • ||||||||||  Journal:  The Role of Growth Hormone Receptor Isoforms and their Effects in Bone Metabolism and Skeletal Fragility. (Pubmed Central) -  Feb 5, 2021   
    In fact, until now, two different isoforms of the GH Receptor (GHR) were described, that differ for the presence or the absence of transcription of the exon 3 of the GHR gene. Both the isoforms produce a functioning receptor, but the exon 3-deleted isoforms (d3-GHR) has a higher sensitivity to endogenous and recombinant GH as compared to the full-length isoform (fl-GHR).
  • ||||||||||  Journal:  Non-adenomatous pituitary tumours mimicking functioning pituitary adenomas. (Pubmed Central) -  Feb 3, 2021   
    The glial cells of the pituitary gland may play an important role in oncogenic differentiation and regulation of the release of hormones. Therefore, attention should be focused on investigating the origin and functions of glial cells.
  • ||||||||||  [VIRTUAL] Cardiovascular Health and Acromegaly (Live) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_2694;    
    Fortunately, such abnormalities seldom evolve into a clearly established cardiomyopathy with fibrosis and the ensuing congestive heart failure. This review will summarize the current approach to cardiovascular co-morbidities in acromegaly and will also speculate about certain biological factors, such as the expression of the different isoforms of the GH receptor, that could be involved in their pathogenesis.
  • ||||||||||  [VIRTUAL] Imaging Monitoring by the Endocrinologist (Live) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_2669;    
    For non-secreting tumors, if not operated,yearly imaging for 5 years and then less frequently to assess for size increase. If operated, if no tumor visible then yearlyfor 5 years and then less frequently but if tumor visible but not increasing,then yearly for 10 years and then less frequently to assess for size increase.
  • ||||||||||  [VIRTUAL] S23. When to Stop Imaging in Pituitary Adenomas? (Live) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_2664;    
    Robust evidence-based protocols on the imaging of pituitary tumors are not available. This session will cover controversies on effective and safe imaging follow-up of patients with sporadic and familial pituitary adenomas (non-functioning pituitary adenomas operated or conservatively managed, Cushings and acromegaly) following various management options.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    [VIRTUAL] Clinical Presentation and Management of Patients With Acromegaly at a University Hospital (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1560;    
    Twelve patients were subsequently excluded from this analysis - nine patients who had been recently diagnosed and were awaiting surgical treatment as well as three patients who had been lost to follow-up. The study sample (n=60) included forty females patients (67%).
  • ||||||||||  [VIRTUAL] The Secret Behind Anemia in Patients With Acromegaly (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1557;    
    Therefore, a comprehensive evaluation is required for anemia in acromegalic patients. Unless otherwise noted, all poster abstracts presented at ENDO 2021 are embargoed until 11 AM Eastern on Saturday, March 20.
  • ||||||||||  thyroxine / Generic mfg., omeprazole / Generic mfg.
    [VIRTUAL] The Pharmacological Burden of Comorbidities in Acromegaly (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1555;    
    Oral medication use with or without fasting was higher in patients with acromegaly. These findings elucidate further physician understanding of the pharmacological burden of acromegaly comorbidities.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
    [VIRTUAL] Use of Oral Concomitant Medications in Patients With Acromegaly (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1552;    
    P3, P4
    In this analysis, most patients with acromegaly receiving LAN, regardless of prior therapy, used ≥1 concomitant oral medication. An awareness of the ongoing burden of comorbidities requiring oral medications should help physicians in managing acromegaly.
  • ||||||||||  bromocriptine / Generic mfg.
    [VIRTUAL] Pituitary Diseases Registry Study in Latvia. Part 1. (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1550;    
    A state register may be set up in the future. Unless otherwise noted, all poster abstracts presented at ENDO 2021 are embargoed until 11 AM Eastern on Saturday, March 20.